MDXXF (Pharmala Biotech Holdings) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 11, 2026)


MDXXF Pharmala Biotech Holdings Inc MDXXF
35 GF Score
Price $0.11
GF Value $0.15
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharmala Biotech Holdings Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pharmala Biotech Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

MDXXF vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Pharmala Biotech Holdings's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Margin of Safety % (DCF FCF Based) falls into.


MDXXF
35GF Score
Pharmala Biotech Holdings Inc MDXXF
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score

Get the complete analysis for MDXXF

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value